Brain Canada is pleased to be partnering once again with the Barbara Turnbull Foundation for Spinal Cord Research to support discoveries that aim to improve the lives of those impacted by injuries to the spinal cord and brain.

The 2022 Turnbull-Tator Award in Spinal Cord Injury and Concussion Research aims to recognize an outstanding publication by an independent researcher at a Canadian institution in the field of spinal cord and/or brain injury research, including concussion, in the last two years, with a $50,000 prize.

Recognizing the important need to build capacity in these fields, the funds awarded through this Award will be utilized to support the salary/ stipend of full-time graduate student(s) or postdoctoral fellow(s) conducting research in the recipient’s laboratory and contributing to the continuation of the excellent research exemplified by the awarded publication.

Evidence clearly shows that increasing equity, diversity, and inclusion (EDI) in research environments enhances excellence, innovation, and creativity. Brain Canada is committed to excellence through equity, and we encourage applicants of diverse backgrounds to apply to our funding opportunities, which will promote the expression of diverse perspectives, approaches, and experiences, including those of underrepresented groups.
 
Click here to view the Request for Application

Deadline for receipt of Applications: November 30, 2022 at 16:00 ET

Partnership Grants are expected to respond to the objectives of the Insight and/or Connection programs. Proposals exclusively for partnered research training initiatives are expected to respond, instead, to the objectives of the Talent program.

These grants provide support for new and existing formal partnerships over four to seven years to advance research, research training and/or knowledge mobilization in the social sciences and humanities. This is done through mutual co-operation and sharing of intellectual leadership, as well as through resources as shown by cash and/or in-kind contributions.

Partnership Grants are intended for large teams of postsecondary institutions and/or organizations of various types that work in formal collaboration.

The quality of training, mentoring and employability plans for students and emerging scholars will be evaluated as an important part of the proposed initiative. SSHRC’s Guidelines for Effective Research Training explain how students and emerging scholars can meaningfully participate in proposed initiatives.

These grants support events and outreach activities geared toward short-term, targeted knowledge mobilization initiatives. These events and activities represent opportunities to exchange knowledge and to engage with participants on research issues of value to them. Events and outreach activities funded by a Connection Grant can often serve as a first step toward more comprehensive and longer-term projects.

Connection Grants support workshops, colloquiums, conferences, forums, summer institutes, or other events or outreach activities that facilitate:

• disciplinary and/or interdisciplinary exchanges in the social sciences and humanities;
• scholarly exchanges between those working in the social sciences and humanities and those working in other research fields;
• intersectoral exchanges between academic researchers in the social sciences and humanities and researchers and practitioners from the public, private and/or not-for-profit sectors; and/or
• international research collaboration and scholarly exchanges with researchers, students and non-academic partners from other countries.

• increase the scientific information available to support regulatory decision-making and oversight

• increase capacity to regulate SMRs

• enhance the capabilities of Canadian universities to undertake research related to SMRs

• increase training and help produce a new generation of nuclear scientists, engineers, and policy makers

The Canadian Hemophilia Society (CHS) is proud to put out its call for applications for its research programs for the 2023-2024 grant period. The deadline to submit applications for all the programs is December 16, 2022. The eligibility criteria and conditions for all our research programs have been revised and updated. Of note, applications must now be done on-line at the links provided on our website under each research program heading and, eligibility has been expanded as follows:

Ø  Dream of a Cure: the program is no longer limited to hemophilia A & B-related projects so that projects focusing on von Willebrand disease, rare factor deficiencies, platelet function disorders (and platelet pathophysiology) and other congenital and acquired bleeding disorders can be supported;

Ø  Dream of a Cure Studentships in Inherited Bleeding Disorders Research: similarly to our basic scientific research program, the studentships are no longer limited to hemophilia-related projects but include all inherited bleeding disorders. Furthermore, science students in any year of an undergraduate program can apply in addition to medical students in any year of training;

Ø  CHS/Pfizer Care Until Cure Research Program: the areas of interest to which investigators are encouraged to submit proposals has been expanded to include mild hemophilia A and B and Factor Utilization & Cost-effectiveness; all projects included but not limited to the list will be considered;

Ø  CHS/Novo Nordisk Psychosocial Research Programme: applications from Social Workers, Nurses, or Physiotherapists with professional experience in a hemophilia treatment centre (or other comparable settings in which care has been provided to people with hemophilia and other inherited bleeding disorders) or persons interested in the field of inherited bleeding disorders will be considered. Students in a PhD program in one of the allied health disciplines may also apply. Professionals who have appointments in universities and who can dedicate time to research are encouraged to apply. Professional experience in a hemophilia treatment centre is desirable but not required.

Ø  CHS/Bayer ADVANCE Canada Research Program:  applicant must be a physician or Ph.D. or professionals from the allied health disciplines (ie. Nursing, Physiotherapy & Social Work) with professional experience in a hemophilia treatment centre (HTC) or other comparable settings in which care has been provided to people with hemophilia and other inherited bleeding disorders. Professionals who have appointments in universities and who can dedicate time to research are encouraged to apply. The proposed research must have relevance to current practice in bleeding disorders care and may incorporate a broad spectrum of quantitative and qualitative research methods addressing professional practice with individuals, families, groups and communities, organizational issues, public health, and education.The research studies should aim to provide better data and tools to help the treaters assist patients in successful ageing.

DREAM OF A CURE

Through funds provided by the Hemophilia Research Million Dollar Club and the CHS, the CHS provides basic scientific research grants and studentships aimed at developing treatments for hemophilia A and B, von Willebrand disease, rare factor deficiencies, platelet function disorders and ultimately, finding a cure.

Dream of a Cure, the CHS Research Program and the 2023 Dream of a Cure Summer Studentships in Inherited Bleeding Disorders Research on-line application forms links as well as the general criteria and conditions are available by accessing the CHS Web site at https://www.hemophilia.ca/chs-dream-of-a-cure-research-program/. For Dream of a Cure, individual grants will be awarded to researchers for one to two years for amounts up to $75,000 per year while support will be offered to interested Canadian medical or science students for up to 4 months for a maximum stipend of $6,000 per student. 

______________________________

CHS / PFIZER CARE UNTIL CURE RESEARCH PROGRAM

You will find at https://www.hemophilia.ca/the-chspfizer-care-until-cure-research-program/ the information and the on-line application link for the CHS/Pfizer Care until Cure Research Program offered by the CHS in collaboration with Pfizer Canada. This program allows Canadian investigators to conduct research on medical and psychosocial aspects of bleeding disorders. Grants for one to two years with a maximum of $75,000 per year will be awarded for clinical research, including outcome evaluation, in fields relevant to improving the health and the quality of life for persons with Hemophilia, persons with von Willebrand disease or other inherited bleeding disorders, persons with related conditions such as HIV or hepatitis C infection, and carriers of an inherited bleeding disorder.

 
______________________________

CHS/NOVO NORDISK CANADA PSYCHOSOCIAL RESEARCH PROGRAMME

The CHS/Novo Nordisk Canada Psychosocial Research Program was created to engage hemophilia program professionals/graduate students from the allied health disciplines (ie. Nursing, Physiotherapy & Social Work) in research activities addressed to understanding the psychosocial impact of hemophilia and other inherited bleeding disorders and to improve the quality of life of persons and families whose lives are affected by these disorders.

The primary intent of this program is to offer one $20,000 research grant.

The major portion of the grant would be to cover the research time for the successful candidate(s), including the time for research assistants. A small amount can be devoted to project expenses.

Multidisciplinary Collaboration:
Collaboration with multidisciplinary care providers and/or between two or more hemophilia centres is accepted and encouraged. Collaboration efforts may include, for example, social work, physical therapy and genetics. It thus may be possible for a hemophilia centre team to jointly submit a cooperative research project. Additionally, inter-regional applications will be considered.
 
Grants will be offered for a one-year period to begin in April 2023.

More detailed information and the on-line application link are available by accessing the CHS Web site at https://www.hemophilia.ca/the-chsnovo-nordisk-psychosocial-research-program/

______________________________

The Canadian Hemophilia Society – Bayer ADVANCE Canada Research Program

The Canadian Hemophilia Society – Bayer ADVANCE Canada Research Program was created to engage Canadian hemophilia treaters in activities to identify and research key issues in the ageing hemophilia population.

The research program will support studies that aim to:

•             Identify and provide insight into key issues associated with the ageing hemophilia population

•             Identify how management of age-related co-morbidities should be adapted to those with hemophilia

•             Create and deliver evidence-based information to health care practitioners (HCPs), the public and policy makers that will lead to improved care and QoL for older Canadians living with hemophilia

The primary intent of this program is to offer one or two $30,000 research grants, to a maximum of $60,000 for one year.

Additional information, the on-line application link, the eligibility criteria and conditions for the research program can be found on our website at this link:

https://www.hemophilia.ca/research-chs-bayer-advance-canada-research-program/

The FY22 Defense Appropriations Act provides funding for the BCRP to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service Members, Veterans, and the general public.  The managing agent for the anticipated funding opportunity is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY22 BCRP funding opportunity announcement for the following award mechanism is posted on the Grants.gov website. 

Applications submitted to the FY22 BCRP must address one or more of the following overarching challenges:

• Prevent breast cancer (primary prevention)
• Identify determinants of breast cancer initiation, risk, or susceptibility
• Distinguish deadly from non-deadly breast cancers
• Conquer the problems of overdiagnosis and overtreatment
• Identify what drives breast cancer growth; determine how to stop it
• Identify why some breast cancers become metastatic
• Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
• Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
• Eliminate the mortality associated with metastatic breast cancer

Funding Opportunities - FY22 Breast Cancer Research Program, Congressionally Directed Medical Research Programs (CDMRP), US DoD (health.mil)

Clinical Research Extension Award - Letter of Intent due November 29, 2022

Investigators at all academic levels (or equivalent)

• Supports research that extends the data collection, follow-up, and analysis of breast cancer clinical research studies.

• The intent of this mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to limited or early termination of patient follow-up and sample collection and analysis.

• Although not all-inclusive, research proposed under this mechanism may entail a deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation, or continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial. • PIs are required to include two or more breast cancer advocates on their research team.

• Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to partner on a single application.

o Each PI is expected to bring a distinct contribution to the application.

o The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. • Submission of a Letter of Intent is required prior to full application submission.

• Clinical trials are not allowed.

The maximum allowable funding for the entire period of performance is $5M for direct costs (plus indirect costs).

• Maximum period of performance is 4 years Partnering PI Option:

• The maximum allowable funding for the entire period of performance is $6M for direct costs (plus indirect costs).

• Maximum period of performance is 4 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcement available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the BCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).

Point of Contact:

CDMRP Helpdesk
301-682-5507                                                                                                                                     
help@eBRap.org

 For more information, please contact Jill Sherman at intl.research@lakeheadu.ca.

INOVAIT is pleased to announce a Canada-wide call for applications from industry and academic members for its third round of pilot funding for collaborative research and development projects in the image-guided therapy (IGT) and artificial intelligence (AI) space. The pilot fund provides up to $125,000 in contributions for pilot projects lasting 9 to 15 months. Applications open October 24, 2022, with the deadline of December 20, 2022. For more information on applying to the pilot fund, go to Funding

Join our webinar on November 2, 2022 to learn more about INOVAIT's Pilot Fund call for applications. This webinar will be in English only, but a video with closed captioning and French subtitles will be available on the INOVAIT website after the webinar.

Register for the webinar.